Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 24, Issue 1, 2005, Pages 17-23

  Hsu, Katherine ^a   Pelton, Stephen ^a   Karumuri, Sudharani ^a,b   Heisey Grove, Dawn ^b   Klein, Jerome ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Childhood invasive pneumococcal infections; Conjugate vaccines; Population surveillance; Serotyping

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE;

ARTICLE; CHILD; COMORBIDITY; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROTYPING; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION; ADOLESCENT; AGE DISTRIBUTION; ETHNOLOGY; INFANT; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; UNITED STATES;

ADOLESCENT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MASSACHUSETTS; MENINGOCOCCAL VACCINES; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROTYPING; VACCINATION;

EID: 13944259416     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000148891.32134.36     Document Type: Article

References (25)

1. MacLeod CM, Hodges RG, Heidelberg M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med. 1945;82:445-465.
2. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49(RR-9):1-35.
3. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine and antibiotic prophylaxis. Pediatrics. 2000;106(2, pt 1):362-366.
4. American Academy of Family Physicians. Pneumococcal conjugate immunization: April 27, 2000. Available at: www.aafp.org/x1556. xml. Accessed June 4, 2003.
5. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage. MMWR. 2001;50:1140-1142.
6. Loughlin AM, Marchant CD, Lett SM. The changing epidemiology of invasive bacterial infections in Massachusetts children, 1984 through 1991. Am J Public Health. 1995;85:392-394.
7. U.S. Census. 1990 data for Massachusetts children younger than 5 years old. Available at: http://factfinder.census.gov/servlet/QTTable?_bm=y& -context=qt&-qr_name=DEC_1990_STF1_QTP1A&-ds_name=DEC_ 1990_STF1_&-CONTEXT=qt&-tree_id=100&-all_geo_types=N&-geo_id= 04000US25&-format=&-_lang=en. Accessed February 8, 2004.
8. U.S. Census. 2000 data for Massachusetts children younger than 5 years old. Available at: http://factfinder.census.gov/servlet/QTTable?_bm= y&-state=qt&-context=qt&-qr_name=DEC_2000_SF1_U_QTP1&-ds_name= DEC_2000_SF1_U&-CONTEXT=qt-tree_id=4001&-all_ geo_types-N&-geo_id= 04000US25&-format=&-_lang=en. Accessed February 8, 2004.
9. U.S. Census. 2000 data for Massachusetts. Available at: http:// factfinder.census.gov/servlet/QTTable?_bm=y&-stateqt&-context =qt&-qr_name=DEC_2000_SF1_U_QTP2&-ds_name=DEC_2000_ SF1_U&-tree_id= 4001&-redoLog=true&-all_geo_types=N&-geo_id=040000US25&-format= &-_lang=en. Accessed February 8, 2004.
10. U.S. Census. 2000 data for Massachusetts. Available at: http://factfinder.census.gov/servlet/DTTable?_bm=y&-state=dt&-context= dt&-ds_ name=DEC_2000_SF1_U&-CONTEXT=dt&-mt_name=DEC_2000_ SF1_U_P004&-tree_id=4001&-redoLog=false&-all_geo_types= N&-geo_id=04000US25&-geo_id=NBSP&-format=&-_lang=en. Accessed February 8, 2004.
11. U.S. Census. 2000 data for Massachusetts. Available at: http://factfinder.census.gov/servlet/DTTable?_bm=y&-state=dt&-context= dt&-ds_ name=DEC_2000_SF1_U&-CONTEXT=dt&-mt_name=DEC_2000_ SF1_U_P006&-tree_id=4001&-redoLog=false&-all_geo_types= N&-geo_id=04000US25&-geo_id=NBSP&-format=&-_lang=en. Accessed February 8, 2004.
12. Black SB, Shinefeld HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:1105-1107.
13. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
14. National Immunization Survey. Estimated vaccination coverage with individual vaccines and selected vaccination series among children 19 to 35 months of age by state, 2002. Available at: http://www2a.cdc.gov/ nip/coverage/nis/nis_iap.asp?fmt=v&rpt=tab3_antigen_state&qtr=Q1/ 2002-Q4/2002. Accessed January 2, 2004.
15. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122-140.
16. Babl FE, Pelton SI, Theodore S, Klein JO. Constancy of distribution of serogroups of invasive pneumococcal isolates among children: experience during 4 decades. Clin Infect Dis. 2001;32:1155-1161.
17. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. Trial of 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
18. Black SB, Shinefeld HR, Ling S, et al. Effectiveness of heptavalent conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.
19. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004;291:2197-2203.
20. Shinefeld H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity, and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002;21:182-186.
21. Park SY, VanBeneden CA, Martin MT, Pilishvili T, Facklam R, Whitney CG. Tracking pneumococcal disease in children receiving the pneumococcal conjugate vaccine. In: 41st Annual Meeting of the Infections Diseases Society of America, October 9-12, 2003. San Diego, CA. Alexandria, VA: Infectious Diseases Society of America, 2003; Abstract 910.
22. Kaplan SL, Mason EO, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States following the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-449.
23. Lee KC, Finkelstein JA, Miroshnik Z, et al. Pediatricians' self-reported clinical practices and adherence to national immunization guidelines after the introduction of pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med 2004;158,695-701.
24. Hsu KK, Pelton SI, Heisey-Grove DM, Hashani S, Klein JD. Sarotype-specific saruoilante for childhood invasive pneumococcal disease. In: 42nd Interscience Conference for Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. Washington, DC: American Society for Microbiology, 2002. Abstract G-1067.
25. Hsu KK, Pelton SI, Heisey-Grove DM, et al. Risk factors for childhood invasive pneumococcal disease in PCV7 era. In: Pediatric Academic Societies' Annual Meeting, May 3-6, 2003, Seattle, WA. Woodlands, TX: Pediatric Academic Societies, 2003. Abstract 1758.